Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics, Inc.    AIMT

AIMMUNE THERAPEUTICS, INC.

(AIMT)
SummaryChartsNewsRatingsCalendarCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU

01/22/2021 | 09:08am EST

Vevey, Switzerland - The European Commission (EC) has approved the use of PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy in the European Union (EU). Developed by Aimmune Therapeutics, Inc., a Nestle Health Science Company, PALFORZIA is an oral immunotherapy indicated in patients aged 4 to 17 years, who have a confirmed diagnosis of peanut allergy. PALFORZIA may be continued in patients 18 years and older and must be used in conjunction with a peanut-avoidant diet.

'Today's news of the EC approval represents the first-ever treatment option approved for peanut allergy in the EU and underscores our vision of providing end-to-end solutions as a driver of wellness and treatment, in the key growth areas of nutrition, metabolism, healthy aging and food allergy,' said Greg Behar, CEO of Nestle Health Science.

Food allergies affect around 17 million people across Europe,1 with peanut allergy being one of the most common of those. In fact, peanut allergy doubled among children between 2005 and 2015,1,2,3 and the number of hospital admissions due to severe allergic reactions increased seven-fold.1 Severe reactions combined with the difficulty of avoiding peanut protein create an urgent need for treatment.4

Andrew Oxtoby, President and CEO of Aimmune Therapeutics, said, 'Now we turn our efforts toward working with health authorities to ensure access to this first-of-kind treatment for those children with peanut allergy for whom our product is appropriate as we prepare to launch in Germany and the UK in May 2021.'

The approval was based on a package of data, including from two phase 3 clinical trials PALISADE and ARTEMIS.5,6,7 In both studies, PALFORZIA treatment resulted in a significant increase in the amount of peanut protein tolerated, compared to placebo.6,7

In Switzerland, a Marketing Authorization Application for PALFORZIA has been filed with Swissmedic and review is currently ongoing.

About PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)]

PALFORZIA is a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts, that can result in the ability to mitigate allergic reactions to the allergen over time.

Results from the two phase 3 clinical trials PALISADE and ARTEMIS showed that more than half of patients treated with PALFORZIA were able to tolerate the equivalent of seven to eight peanut kernels after nine to twelve months of treatment. This data highlights PALFORZIA's potential to mitigate against allergic reactions, including anaphylaxis in the event of unintended exposure to peanut protein.6,7 PALFORZIA is not intended for, and does not provide, immediate relief of allergic symptoms.

The safety profile was as expected for an oral desensitization therapy. The most common adverse reactions (of any severity) were abdominal pain (49.4%), throat irritation (40.7%), pruritus (33.7%), nausea (33.2%), vomiting (28.5%), urticaria (28.5%), oral pruritus (26.0%), abdominal discomfort (22.9%), and abdominal pain upper (22.8%).5

Contacts:

Media:

Christoph Meier Tel.: +41 21 924 2200

mediarelations@nestle.com

Jacquelyn Campo Tel.: +41 21 924 3855

NestleHealthScience.External@nestle.com

Investors:

Luca Borlini Tel.: +41 21 924 3509

ir@nestle.com

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
NESTLÉ S.A. 0.05% 96.75 Delayed Quote.-7.25%
All news about AIMMUNE THERAPEUTICS, INC.
02/18PRESS RELEASE : Nestle: Nestlé reports full-year -2-
DJ
01/22AIMMUNE THERAPEUTICS : European Commission approves Aimmune's PALFORZIA as first..
AQ
01/05AIMMUNE THERAPEUTICS : European Commission approves first treatment for peanut a..
AQ
2020AIMMUNE THERAPEUTICS : European Commission approves Aimmune's PALFORZIA as first..
AQ
2020AIMMUNE THERAPEUTICS : European Commission Approves Aimmune's PALFORZIA® as Firs..
BU
2020Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
2020AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Com..
AQ
2020AIMMUNE THERAPEUTICS : Receives Positive CHMP Opinion on PALFORZIA for the Treat..
AQ
2020MONTEVERDE & ASSOCIATES PC : Files Class Action Lawsuit On Behalf Of Shareholder..
PR
2020AIMMUNE THERAPEUTICS : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
More news
Chart AIMMUNE THERAPEUTICS, INC.
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | AIMT | US00900T1079 | MarketScreener
Managers and Directors
NameTitle
Jayson Donald Alexander Dallas President, Chief Executive Officer & Director
Mark D. McDade Chairman
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Patrick G. Enright Independent Non-Employee Director
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS, INC.0.00%2 268
GILEAD SCIENCES, INC.10.49%79 825
WUXI APPTEC CO., LTD.15.05%58 463
VERTEX PHARMACEUTICALS-9.05%56 266
REGENERON PHARMACEUTICALS-2.64%48 743
BEIGENE, LTD.27.47%30 411